Rules, risks, and reality: rethinking gene therapy eligibility

Key Points

• Gene therapy eligibility must be reconsidered to balance access and risk management.
• The analysis reveals that many genetic disorders could benefit from broadening existing eligibility criteria.
• Assessment using patient data explores the implications of expanding access to gene therapy for effective treatment.
• The findings highlight the importance of understanding risks involved in gene therapy to guide future clinical applications.